PROTAGONIST THERAPEUTICS INC stock forecast: down to 30.35 USD PTGX stock price prognosis


Forecast for Fri 17 Dec 2021 price 27.56

PROTAGONIST THERAPEUTICS INC stock price forecast for further price development down to -1.97% (time horizon: 1 day) and price target of 30.35 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) PROTAGONIST THERAPEUTICS INC share price prediction for 2021-12-17 with daily closed price projections

Key Facts

Symbol PTGX 

ISIN US74366E1029 

CUSIP 74366E102

Currency USD

Category Pharmaceutical Preparations

Forecast price change %

News sentiment (-0.33)

Finance numbers

Revenue 31,170,000.0

Earnings per share -1.74

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

Our clinical assets are all derived from our proprietary discovery platform. PV is typically caused by a form of Janus Kinase 2 ("JAK2") mutation. The primary efficacy endpoint in NTD patients was a change in hemoglobin from baseline. As a result, they can be associated with infection and malignancy risk. Rapid clearance may be beneficial especially if patients need to discontinue therapy. PN-943 Phase 2 Clinical Trial OverviewFigure 6. Conjugation strategies are used to optimize the exposure of the injected peptide. A decision from the FDA on this application is expected in early 2021. However, trade secrets can be difficult to protect. We work with contract manufacturers in the United States, Europe and Asia. The FDA may request additional information rather than accept an NDA for filing. Safeguarding the health and safety of our employees is our top priority. We will remain an emerging growth company until December 31, 2021. &# We control only certain aspects of their activities. We will thus be subject to the risks of doing business outside of the United States.

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 45.19/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
BVF INC/IL 2021-03-31 3959451
Tri Locum Partners LP 2021-03-31 257086
Hartford Financial Management Inc. 2021-06-30 300

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Mt Vernon Street Trust 2021-05-31 141975 Long
Fidelity Concord Street Trust 2021-05-31 71859 Long
Fidelity Advisor Series I 2021-05-31 16800 Long
Fidelity Salem Street Trust 2021-04-30 260073 Long
Fidelity Concord Street Trust 2021-04-30 7329 Long


CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1120477 Patel Dinesh V Ph D 2021-01-19 SALE Accept Accept Accept Accept
1675881 Liu David Y 2021-08-17 SALE Accept 0 0 0
1706301 Noonberg Sarah B. 2021-02-11 SALE Accept Accept Reject Accept

PROTAGONIST THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

On-Balance Volume information for PROTAGONIST THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for PROTAGONIST THERAPEUTICS INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for PROTAGONIST THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for PROTAGONIST THERAPEUTICS INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for PROTAGONIST THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for PROTAGONIST THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for PROTAGONIST THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2021-11-01 30.35 2021-10-23 06:01
2021-11-02 24.34 2021-10-23 06:01
2021-11-03 27.44 2021-10-23 06:01
2021-11-04 26.88 2021-10-23 06:01
2021-11-05 26.93 2021-10-23 06:01
2021-11-08 27.20 2021-10-23 06:01
2021-10-25 31.08 2021-10-23 06:01
2021-10-26 30.79 2021-10-23 06:01
2021-10-27 29.58 2021-10-23 06:01
2021-10-28 30.31 2021-10-23 06:01
2021-10-29 30.07 2021-10-23 06:01
2021-11-09 27.50 2021-10-23 06:01
2021-11-10 27.30 2021-10-23 06:01
2021-11-11 26.91 2021-10-23 06:01
2021-11-12 26.77 2021-10-23 06:01
2021-11-15 26.62 2021-10-23 06:01
2021-11-16 26.50 2021-10-23 06:01
2021-11-17 26.77 2021-10-23 06:01
2021-11-18 27.49 2021-10-23 06:01
2021-11-19 26.75 2021-10-23 06:01
2021-11-22 27.00 2021-10-23 06:01
2021-11-23 26.74 2021-10-23 06:01
2021-11-24 28.82 2021-10-23 06:01
2021-11-25 27.07 2021-10-23 06:01
2021-11-26 27.67 2021-10-23 06:01
2021-11-29 27.63 2021-10-23 06:01
2021-11-30 27.39 2021-10-23 06:01
2021-12-01 27.35 2021-10-23 06:01
2021-12-02 27.50 2021-10-23 06:01
2021-12-03 27.62 2021-10-23 06:01
2021-12-06 27.51 2021-10-23 06:01
2021-12-07 27.68 2021-10-23 06:01
2021-12-08 27.67 2021-10-23 06:01
2021-12-09 27.48 2021-10-23 06:01
2021-12-10 27.15 2021-10-23 06:01
2021-12-13 27.61 2021-10-23 06:01
2021-12-14 27.35 2021-10-23 06:01
2021-12-15 27.50 2021-10-23 06:01
2021-12-16 26.76 2021-10-23 06:01
2021-12-17 27.56 2021-10-23 06:01